TaiGen Biopharmaceuticals Holdings (ROCO:4157) Ending Cash Position: NT$155.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
62 GF Score
Price NT$9.06
GF Value NT$28.96
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings Ending Cash Position?

TaiGen Biopharmaceuticals Holdings ROCO:4157 62 Ending Cash Position is NT$155.1 Mil as of Jun. 2026. GuruFocus rates ROCO:4157 with a GF Score™ of 62/100 and a GF Value™ of NT$28.96 (Possible Value Trap). The stock has 3 warning signs investors should review.

TaiGen Biopharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$155.1 Mil.

TaiGen Biopharmaceuticals Holdings's quarterly Ending Cash Position declined from Dec. 2025 (NT$145.1 Mil) to Mar. 2026 (NT$121.0 Mil) but then increased from Mar. 2026 (NT$121.0 Mil) to Jun. 2026 (NT$155.1 Mil).

TaiGen Biopharmaceuticals Holdings's annual Ending Cash Position declined from Dec. 2023 (NT$374.7 Mil) to Dec. 2024 (NT$74.1 Mil) but then increased from Dec. 2024 (NT$74.1 Mil) to Dec. 2025 (NT$145.1 Mil).

TaiGen Biopharmaceuticals Holdings Ending Cash Position Related Terms

TaiGen Biopharmaceuticals Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings Ending Cash Position Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 364.93 244.01 374.66 74.14 145.09

TaiGen Biopharmaceuticals Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.99 69.36 145.09 121.00 155.11
ROCO:4157
62GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TaiGen Biopharmaceuticals Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=64.116+80.971
=145.1

TaiGen Biopharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=131+24.106
=155.1

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$155.1 Mil mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Ending Cash Position of NT$155.1 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors.
Is TaiGen Biopharmaceuticals Holdings' Ending Cash Position too high?
TaiGen Biopharmaceuticals Holdings' current Ending Cash Position is NT$155.1 Mil. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Ending Cash Position compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' Ending Cash Position of NT$155.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current Ending Cash Position is NT$155.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Possible Value Trap. The stock's GF Value™ is NT$28.96, compared to a current price of NT$9.06 — trading 68.7% below its estimated fair value. The current Ending Cash Position is NT$155.1 Mil. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Ending Cash Position is NT$155.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$9.06 is trading 68.7% below its estimated GF Value™ of NT$28.96. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Possible Value Trap.

Key valuation signals for ROCO:4157:

  • Ending Cash Position: NT$155.1 Mil
  • GF Value™: NT$28.96 vs. price of NT$9.06 (68.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
62GF Score

Get the complete analysis for ROCO:4157

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$9.06
Price
NT$28.96
GF Value